Amoy Diagnostics Co Ltd Net Assets
Amoy Diagnostics Co Ltd net assets. Based on the latest financial reports, Amoy Diagnostics Co Ltd (300685) has net assets worth CN¥1.89 Billion CNY (≈ $277.18 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.21 Billion ≈ $324.08 Million USD) and total liabilities (CN¥320.47 Million ≈ $46.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Amoy Diagnostics Co Ltd (300685) net asset quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.89 Billion |
| % of Total Assets | 85.53% |
| Annual Growth Rate | 44.45% |
| 5-Year Change | 50.11% |
| 10-Year Change | 567.72% |
| Growth Volatility | 57.52 |
Net Assets of Amoy Diagnostics Co Ltd (2012–2025)
Net assets of Amoy Diagnostics Co Ltd from 2012 to 2025. This chart illustrates how Amoy Diagnostics Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore net asset growth rate of Amoy Diagnostics Co Ltd to track the company's year-over-year net asset growth rate.
Annual Net Assets for Amoy Diagnostics Co Ltd (2012–2025)
The table below shows the annual net assets of Amoy Diagnostics Co Ltd from 2012 to 2025. For live market cap and overall valuation, see how much is Amoy Diagnostics Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.06 Billion ≈ $300.85 Million |
+11.54% |
| 2024-12-31 | CN¥1.84 Billion ≈ $269.73 Million |
+8.22% |
| 2023-12-31 | CN¥1.70 Billion ≈ $249.25 Million |
+13.58% |
| 2022-12-31 | CN¥1.50 Billion ≈ $219.46 Million |
+9.50% |
| 2021-12-31 | CN¥1.37 Billion ≈ $200.42 Million |
+21.37% |
| 2020-12-31 | CN¥1.13 Billion ≈ $165.13 Million |
+25.10% |
| 2019-12-31 | CN¥902.11 Million ≈ $132.01 Million |
+19.21% |
| 2018-12-31 | CN¥756.74 Million ≈ $110.73 Million |
+16.56% |
| 2017-12-31 | CN¥649.20 Million ≈ $95.00 Million |
+110.84% |
| 2016-12-31 | CN¥307.91 Million ≈ $45.06 Million |
+24.20% |
| 2015-12-31 | CN¥247.90 Million ≈ $36.28 Million |
+183.20% |
| 2014-12-31 | CN¥87.54 Million ≈ $12.81 Million |
+122.74% |
| 2013-12-31 | CN¥39.30 Million ≈ $5.75 Million |
+127.82% |
| 2012-12-31 | CN¥17.25 Million ≈ $2.52 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Amoy Diagnostics Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 139585329426.0% over the analyzed period, indicating profitable operations and earnings retention.
Amoy Diagnostics Co Ltd Net Assets Breakdown (December 2025)
Amoy Diagnostics Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.39 Billion | 67.77% |
| Other Components | CN¥662.54 Million | 32.23% |
| Total Equity | CN¥2.06 Billion | 100.00% |
Amoy Diagnostics Co Ltd Competitors by Market Cap
The table below lists competitors of Amoy Diagnostics Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Playtech plc
F:PL8
|
$1.13 Billion |
|
Nokian Renkaat Oyj
HE:TYRES
|
$1.13 Billion |
|
Anhui Guofeng Plastic Industry Co Ltd
SHE:000859
|
$1.13 Billion |
|
SDI Corp
TW:2351
|
$1.13 Billion |
|
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
|
$1.13 Billion |
|
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
|
$1.13 Billion |
|
Genco Shipping & Trading Ltd
NYSE:GNK
|
$1.13 Billion |
|
Hunan Friendship&Apollo Commercial Co Ltd
SHE:002277
|
$1.13 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amoy Diagnostics Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,843,264,757 to 2,055,946,404, a change of 212,681,647 (11.5%).
- Net income of 357,886,600 contributed positively to equity growth.
- Dividend payments of 118,947,539 reduced retained earnings.
- Other comprehensive income decreased equity by 2,142,883.
- Other factors decreased equity by 24,114,531.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥357.89 Million | +17.41% |
| Dividends Paid | CN¥118.95 Million | -5.79% |
| Other Comprehensive Income | CN¥-2.14 Million | -0.1% |
| Other Changes | CN¥-24.11 Million | -1.17% |
| Total Change | CN¥- | 11.54% |
Book Value vs Market Value Analysis
This analysis compares Amoy Diagnostics Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 342.00x to 3.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.06 | CN¥19.79 | x |
| 2013-12-31 | CN¥0.13 | CN¥19.79 | x |
| 2014-12-31 | CN¥0.23 | CN¥19.79 | x |
| 2015-12-31 | CN¥0.82 | CN¥19.79 | x |
| 2016-12-31 | CN¥1.06 | CN¥19.79 | x |
| 2017-12-31 | CN¥1.94 | CN¥19.79 | x |
| 2018-12-31 | CN¥1.95 | CN¥19.79 | x |
| 2019-12-31 | CN¥2.32 | CN¥19.79 | x |
| 2020-12-31 | CN¥2.82 | CN¥19.79 | x |
| 2021-12-31 | CN¥3.42 | CN¥19.79 | x |
| 2022-12-31 | CN¥3.81 | CN¥19.79 | x |
| 2023-12-31 | CN¥4.30 | CN¥19.79 | x |
| 2024-12-31 | CN¥4.63 | CN¥19.79 | x |
| 2025-12-31 | CN¥5.17 | CN¥19.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amoy Diagnostics Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.41%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.88%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.14x
- Recent ROE (17.41%) is below the historical average (21.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 46.22% | 20.90% | 0.57x | 3.88x | CN¥6.25 Million |
| 2013 | 56.11% | 29.65% | 0.67x | 2.81x | CN¥18.12 Million |
| 2014 | 21.86% | 17.92% | 0.61x | 2.02x | CN¥10.39 Million |
| 2015 | 8.75% | 11.92% | 0.58x | 1.26x | CN¥-3.00 Million |
| 2016 | 21.77% | 26.50% | 0.72x | 1.15x | CN¥36.24 Million |
| 2017 | 14.49% | 28.47% | 0.48x | 1.07x | CN¥29.15 Million |
| 2018 | 16.75% | 28.87% | 0.54x | 1.08x | CN¥51.06 Million |
| 2019 | 15.02% | 23.42% | 0.55x | 1.16x | CN¥45.26 Million |
| 2020 | 15.98% | 24.76% | 0.56x | 1.15x | CN¥67.48 Million |
| 2021 | 17.56% | 26.12% | 0.60x | 1.11x | CN¥103.12 Million |
| 2022 | 17.59% | 31.32% | 0.51x | 1.10x | CN¥113.77 Million |
| 2023 | 15.35% | 25.06% | 0.54x | 1.14x | CN¥91.15 Million |
| 2024 | 13.83% | 22.98% | 0.54x | 1.12x | CN¥70.54 Million |
| 2025 | 17.41% | 29.88% | 0.51x | 1.14x | CN¥152.29 Million |
Industry Comparison
This section compares Amoy Diagnostics Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,675,595,020
- Average return on equity (ROE) among peers: 7.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amoy Diagnostics Co Ltd (300685) | CN¥1.89 Billion | 46.22% | 0.17x | $1.13 Billion |
| Berry Genomics Co Ltd (000710) | $1.72 Billion | -11.22% | 0.39x | $499.21 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $2.55 Billion | 10.32% | 1.25x | $1.86 Billion |
| Hangzhou Tigermed Consulting (300347) | $916.90 Million | 13.69% | 0.48x | $5.20 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $3.42 Billion | 3.28% | 0.16x | $1.07 Billion |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.93 Billion | 8.79% | 0.26x | $539.32 Million |
| Maccura Biotechnology Co Ltd (300463) | $6.53 Billion | 10.85% | 0.25x | $796.34 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $344.60 Million | 18.42% | 0.12x | $551.54 Million |
| BGI Genomics Co Ltd (300676) | $4.46 Billion | 6.20% | 0.34x | $2.35 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.21 Billion | 7.60% | 0.15x | $585.50 Million |
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more